You are here: Industry Insights > Alphamab Oncology

News List

Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052 prnasia
February 14, 2022
Alphamab Oncology (stock code: 9966.HK) announced, that the company received the IND approval from the National Medical Products Administration (NMPA) for the company's innovative bispecific antibody KN052...
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046 prnasia
January 13, 2022
Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203)...
Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046 prnasia
December 23, 2021
Alphamab Oncology (stock code: 9966 HK) announced dosing of the first patient of its proprietary PD-L1/CTLA-4 bispecific antibody KN046 in the United States.
IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer was Approved by CDE prnasia
November 24, 2021
Alphamab Oncology (stock code: 9966.HK) announced that the IND application for phase 3 registration study (KN046-303) of the PD-L1/CTLA-4 bispecific antibody KN046 plus nab-paclitaxel/gemcitabine...
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC prnasia
October 29, 2021
Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-02) recently completed the first drug administration.
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE prnasia
October 21, 2021
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026...
Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046 prnasia
October 18, 2021
Alphamab Oncology (stock code: 9966.HK), announced that the first phase III pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-01) has successfully completed enrollment of all patients.